Previous Article | Next Article ![]()
Clinical and Diagnostic Laboratory Immunology, May 2000, p. 515-518, Vol. 7, No. 3
Unité INSERM
U4301 and Laboratoire de
Virologie,4 Hôpital Broussais, and
Université Pierre et Marie Curie (Paris
VI),3 Paris, and Département de
Pathologie, Université Paris-Sud (Paris XII), Hôpital Henri
Mondor, Créteil,2 France
Received 21 October 1999/Returned for modification 19 January
2000/Accepted 28 February 2000
In the present study, we demonstrate that recombinant human
secretory leukocyte protease inhibitor (rhSLPI) inhibits infection of
lymphocyte- and monocyte-derived tumor cell lines and peripheral blood
lymphocytes with laboratory-adapted isolates and with the primary
isolate, NDK, of free human immunodeficiency virus type 1 (HIV-1). In
contrast, rhSLPI did not exhibit inhibitory activity toward
transcytosis of cell-associated HIV-1 through a tight monolayer of
endometrial epithelial cells. These observations indicate that the
inhibitory effect of SLPI is restricted to free HIV-1 in corporal fluids.
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Secretory Leukocyte Protease Inhibitor Inhibits
Infection of Monocytes and Lymphocytes with Human Immunodeficiency
Virus Type 1 but Does Not Interfere with Transcytosis of
Cell-Associated Virus across Tight Epithelial Barriers
*
Corresponding author. Mailing address: Unité
INSERM U430, Hôpital Broussais, 96, rue Didot, 75674 Paris Cedex
14, France. Phone: 331 43 95 80 53. Fax: 331 43 95 80 55. E-mail:
laurent.belec{at}brs.ap-hop-paris.fr.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»